-
Neuromyelitis Spectrum Disorder (NMOSD)'s first B cell depleting agent!
Time of Update: 2021-04-19
com/monoclonalDrugs/" target="_blank">monoclonal antibody drug Uplizna (MEDI-551, generic name: inebilizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) , Optic neuromyelitis) patients to prevent disease recurrence.
-
Cell Reports | Li Xuekun/Yi Wen/Shu Qiang team reveals the molecular mechanism of glycosylation regulating adult neurogenesis
Time of Update: 2021-04-19
In summary, this work clarifies that Ogt-mediated O-GlcNAc modification regulates the Notch signaling pathway by antagonizing Itch-mediated Notch1 ubiquitination, thereby maintaining the important mechanism of mouse adult neural stem cell homeostasis and adult neurogenesis.
-
Cell Death Differ︱ Zheng Ruimao's team discovers a new mechanism related to Parkinson's disease
Time of Update: 2021-04-19
>Withaferin A, whose Chinese name is Ashwagandha A, is a steroidal ester isolated from Ashwagandha [5]. As a natural drug compound that can penetrate the blood-brain barrier, buburnin A has
-
Prof. Dehui Zou: Treatment progress and future prospects of B-cell lymphoma
Time of Update: 2021-04-19
Professor Zou Dehui In recent years, Chimeric Antigen Receptor (CAR) T-cell therapy has brought revolutionary progress in the treatment of lymphoma.
-
The latest research progress of neural stem cells (Phase 5)
Time of Update: 2021-04-19
html" target="_blank">Sci Rep: Research reveals that adult neural stem cell biomarkers doi:10.
html" target="_blank">Sci the Rep: Adult neural stem cell studies revealed biomarker bioon.
-
: the high output of the School of Life Sciences, the dual implementation of cell therapy and precise diagnosis
Time of Update: 2021-04-19
and Transformation Research. The laboratory focuses on "biological size, function, regulation and disease" and relies on the foundation of early organ growth regulation work. , Use genetics, cell biology, biochemical physical methods
-
Nature Back to Back | New insights into the pathogenesis of non-alcoholic fatty liver: CD8 T cells launch self-attack
Time of Update: 2021-04-19
Knolle of Molecular Immunology at the Technical University of Munich published an article titled Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH in Nature.
-
Cell new article: Some new coronavirus mutations can escape neutralizing antibodies
Time of Update: 2021-04-19
In order to accelerate the research progress of the new crown virus, Yiqiao Shenzhou specially launched: new crown recombinant protein, cytokine, ELISA kit, gene and other four categories of products are 40% off, and 30,000+ products are on hot promotion!
-
Professor Junning Cao: Research Progress of Extranodal NK/T Cell Lymphoma|The 4th China Conference on Individualized Lymphoma Treatment
Time of Update: 2021-04-19
At a median follow-up of 17 months, the 3-year progression-free survival (PFS) rate of NK/T-cell lymphoma patients reached 57.
-
Professor Fan Lei: Diagnosis and Treatment of Mantle Cell Lymphoma|The 4th China Conference on Chronic Lymphocytic Leukemia
Time of Update: 2021-04-19
The results of the study showed that the R-BAC chemotherapy regimen (rituximab, bendamustine, cytarabine) achieved 83% ORR, CR rate 60%, and PFS in MCL patients after BTK inhibitor treatment failed.
-
Sub-Journal of "Cell": Muscles are quietly protecting the brain!
Time of Update: 2021-04-19
Obviously, Amyrel is a key stress-induced muscle growth factor, which can improve the protein balance in the aging process and has a protective effect on neurodegeneration induced by pathogenic proteins.
-
The first | Targeted BCMA CAR-T cell therapy was approved for marketing!
Time of Update: 2021-04-19
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> 544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> The approval is based on data from the pivotal phase 2 clinical trial KarMMa, which treated 127 patients with relapsed/refractory multiple myeloma who received at least three pre-therapies, including immunomodulators and proteases.
-
Sub-Journal of "Cell": Beware of venous thrombosis related to immunotherapy!
Time of Update: 2021-04-18
cells after the ban has been lifted. The increase in the number of humoral immunity, cytokines, or autoantibodies will all cause adverse reactions in immune-related organs to varying degrees. If you have
-
Cell Metab | Skeletal muscle-derived signals can hinder brain neurodegeneration
Time of Update: 2021-04-18
caused higher maltose levels in the head and body of Drosophila, while glucose levels were not consistently regulated. So is maltose a key regulator of protein quality control? The authors found that treatment with recombinant
-
Cancer Cell: The molecular mechanism of key protein-mediated tumor immune tolerance
Time of Update: 2021-04-18
023 Original source: Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance.
-
Cancer Cell: p53 mutations affect natural immune signals and promote tumor immune escape
Time of Update: 2021-04-18
="text-align: justify;"> (Figure 1, p53 mutation inhibits the transmission of natural immune cells)
-
Sub-Journal of "Cell": Intestinal bacteria, you are paving the way for the metastasis of intestinal cancer!
Time of Update: 2021-04-18
are waiting for you at Singularity. References: 1. Bertocchi A, Carloni S, Ravenda PS, et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer
-
Professor Zhang Xi: How to combine CAR-T cell therapy with clinical needs
Time of Update: 2021-04-18
Professor Zhang Xi took the team's development history of CAR-T cell research and development in recent years as an example, and vividly demonstrated their efforts in combining CAR-T with clinical needs.
-
Professor Han Baohui: Atelizumab is expected to become a new choice for the first-line treatment of advanced non-small cell lung cancer
Time of Update: 2021-04-18
S. Food and Drug Administration (FDA) with the success of the IMpower110 study Atilizumab is the first-line treatment for patients with metastatic NSCLC with high PD-L1 expression (TC≥50% or IC≥10%) [1].
-
Cover of Science Immunology | Dr. Zhang Shengbo and others reveal the key transcription factor DC
Time of Update: 2021-04-18
Michael Chopin from the WEHI Institute of the University of Melbourne published a research paper titled Type 1 conventional dendritic cell fate and function are controlled by DC-SCRIPT online in Science Immunology.
